Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition - PubMed (original) (raw)
Review
doi: 10.1038/nrc2152.
Affiliations
- PMID: 17522716
- DOI: 10.1038/nrc2152
Review
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Henk M W Verheul et al. Nat Rev Cancer. 2007 Jun.
Abstract
Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor signalling pathways that are important for maintaining homeostasis. Experiences with angiogenesis inhibitors in clinical trials indicate that short-term toxicities are mostly manageable. However, these agents will also be given in prolonged treatment strategies, so we need to anticipate possible long-term toxicities. In addition, understanding the molecular mechanisms involved in the toxicity of angiogenesis inhibition should allow more specific and more potent inhibitors to be developed.
Similar articles
- Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Kappers MH, van Esch JH, Sleijfer S, Danser AH, van den Meiracker AH. Kappers MH, et al. J Hypertens. 2009 Dec;27(12):2297-309. doi: 10.1097/HJH.0b013e3283309b59. J Hypertens. 2009. PMID: 19680138 Review. - The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
Tocchetti CG, Gallucci G, Coppola C, Piscopo G, Cipresso C, Maurea C, Giudice A, Iaffaioli RV, Arra C, Maurea N. Tocchetti CG, et al. Eur J Heart Fail. 2013 May;15(5):482-9. doi: 10.1093/eurjhf/hft008. Epub 2013 Jan 16. Eur J Heart Fail. 2013. PMID: 23325019 Review. - Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
Dobbin SJH, Cameron AC, Petrie MC, Jones RJ, Touyz RM, Lang NN. Dobbin SJH, et al. Heart. 2018 Dec;104(24):1995-2002. doi: 10.1136/heartjnl-2018-313726. Epub 2018 Sep 18. Heart. 2018. PMID: 30228246 Free PMC article. Review. - Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. van Heeckeren WJ, et al. J Clin Oncol. 2007 Jul 20;25(21):2993-5. doi: 10.1200/JCO.2007.11.5113. J Clin Oncol. 2007. PMID: 17634476 No abstract available. - Biological mechanisms of bevacizumab-associated adverse events.
Higa GM, Abraham J. Higa GM, et al. Expert Rev Anticancer Ther. 2009 Jul;9(7):999-1007. doi: 10.1586/era.09.68. Expert Rev Anticancer Ther. 2009. PMID: 19589038 Review.
Cited by
- Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.
Chen CT, Hung MC. Chen CT, et al. Am J Transl Res. 2013 May 24;5(4):393-403. Print 2013. Am J Transl Res. 2013. PMID: 23724163 Free PMC article. - Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Kawaratani H, Tsujimoto T, Fukui H. Yoshiji H, et al. Oncol Lett. 2011 Jan;2(1):69-73. doi: 10.3892/ol.2010.196. Epub 2010 Oct 5. Oncol Lett. 2011. PMID: 22870131 Free PMC article. - Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.
Raschi E, De Ponti F. Raschi E, et al. Intern Emerg Med. 2012 Apr;7(2):113-31. doi: 10.1007/s11739-011-0744-y. Epub 2011 Dec 13. Intern Emerg Med. 2012. PMID: 22161318 Review. - Visualization of Kinase Inhibition-Related Adverse Events Using the Japanese Adverse Drug Event Report Database.
Mizuno T, Sakai T, Tanabe K, Umemura T, Goto N, Ohtsu F. Mizuno T, et al. Drugs Real World Outcomes. 2021 Jun;8(2):197-206. doi: 10.1007/s40801-021-00235-w. Epub 2021 Mar 9. Drugs Real World Outcomes. 2021. PMID: 33686612 Free PMC article. - Role of placenta growth factor in cancer and inflammation.
Kim KJ, Cho CS, Kim WU. Kim KJ, et al. Exp Mol Med. 2012 Jan 31;44(1):10-9. doi: 10.3858/emm.2012.44.1.023. Exp Mol Med. 2012. PMID: 22217448 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources